Multidisciplinary Management of Rectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 58
Special Issue Editor
Special Issue Information
Dear Colleagues,
The multidisciplinary management of rectal cancer has significantly evolved in recent years. The management of rectal cancer remains challenging and has changed over the years, involving imaging, endoscopy, pathology, surgery, radiotherapy, and clinical oncology.
While neoadjuvant radiotherapy (NA-RT) of a long-course schedule combined with chemotherapy or a short-course schedule followed by total mesorectal excision surgery has been the standard of care for locally advanced rectal cancer, there is increasing interest in a total neoadjuvant therapy (TNT) strategy, including NA-RT with induction or consolidation chemotherapy. Following major clinical trials, such as the RAPIDO, PRODIGE 23, and CAO/ARO/AIO-12 trials, several issues, including patient selection, chemotherapy regimens, state-of-the-art radiotherapy modality, and the best sequence of chemotherapy and NA-RT in TNT, are current areas of further investigations. In addition, the watch-and-wait strategy has been investigated and could become a treatment option.
Multidisciplinary management plays an important role in the treatment of recurrent or metastatic rectal cancer. Surgery and high-precision radiotherapy, such as stereotactic body radiotherapy and particle therapy, are indicated for a curative intent for a limited number of metastases and local recurrence. In addition, palliative radiotherapy can relieve symptoms of advanced rectal cancer.
In this Special Issue, we welcome a wide range of original research articles and reviews. This Special Issue aims to publish articles that highlight recent advances in multidisciplinary management, including surgery, chemotherapy, radiotherapy, imaging, and biomarkers, of early-stage and advanced rectal cancers.
We look forward to receiving your contributions.
Dr. Hiroshi Doi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rectal cancer
- neoadjuvant radiotherapy
- preoperative radiotherapy
- total neoadjuvant therapy
- watch-and-wait strategy
- stereotactic body radiotherapy
- particle therapy
- therapeutic response assessment
- biomarkers
- radiomics
